Abcam provides a range of antibodies, proteins, kits, and reagents for life science research, self-described as helping life scientists worldwide deliver faster breakthroughs.

Abcam

Discovery Drive

Domain Not Resolving

Google Font API

Google Maps

WordPress

Amazon

Font Awesome

LetsEncrypt

reCAPTCHA

IPv6

Apache

President

Bret Camp

Finance Lead Business Process Owner - Transformations

Paul Grimes

Chairman

Peter Allen

Senior Vice President Research & Development

Alejandra Solache

VP People Experience

Danielle Norby

SVP, Supply Chain & Manufacturing

Jac Price

Senior Vice President Marketing

John Baker

Human Resources & Workplace Transition Leader - Abcam/Danaher Acquisition

Jon Sale

VP Custom Solutions

Joyce Young

CDIO (SVP Digital, Data and Technology)

Juan Sacristan

Louise Patten

Mara Aspinall

Jim Warwick

Tony Kouzarides

Co-Founder

Beni Baixauli

RPA Analyst

Jonathan Milner

Founder

Gavin Wood

Chief Financial Officer

Daniel C. Pregibon

General Manager & Platform Innovation

Conor Rafferty

Director of Computational R&D

Helen Rabe

Global CSO

Europe, Middle East, and Africa (EMEA) Acquired Companies With Less Than $500M in Revenue (Top 10K)

Europe Companies With More Than $10M in Revenue (Top 10K)

Biotechnology Acquired Companies With More Than 50 Employees

United Kingdom Companies With More Than 10 Employees (Top 10K)

Abcam helps researches with breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

HSBC

Post-IPO Equity - Abcam

Venture Round - Abcam

Cambridge

Cambridgeshire

United Kingdom

Europe

What is Abcam’s founder, Jonathan Milner, up to?

Proteomics Market Set to Surge: Aiming for USD 96.35 Billion by 2032, Driven by Rising Demand for Personalized Medicine and Technological Advancements

Fire and security firm ABCA Systems buys three firms in North West

Epigenetics Market Projected to Exceed USD 12.7 Bn by 2033, Bio-Rad Laboratories, Inc., Abcam Plc.,

Macrophage Marker Market to See Booming Growth 2024-2031 | Abcam plc, Bio-Rad Laboratories, GeneTex, Inc,

Abcam most cited antibody supplier for IHC in 2023 – Abcam Limited

Abcam most cited antibody supplier for IHC in 2023 – Abcam plc

Abcam appoints Markus Lusser as new President – Abcam plc

Abcam appoints Markus Lusser as new President

Danaher completes $5.7 billion Abcam acquisition | Business

Abcam provides a wide range of antibodies validated for research use, supporting various scientific studies.

Abcam offers proteins for research applications, aiding in the study of biological processes.

Abcam supplies kits and reagents for life science research, facilitating experimental procedures.

United States

North America

China

Asia

India

Japan

HTML5

jQuery

Google Analytics

Oracle Eloqua

Akamai Intelligent Platform

GoDaddy

Bootstrap

DigiCert

Wordpress

Thawte SSL

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Abcam plc

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 24, 2024 6:14 PM	3654d372
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 24, 2024 6:14 PM	b8504c77
crunchbase trigger	general	Nov 25, 2024 9:09 AM	32829d69
crunchbase profile	general	Nov 25, 2024 9:16 AM	481f0051
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:59 PM	3c4ee8f9
peers	general	Oct 24, 2024 6:14 PM	789d5ed5
news basic	general	Oct 24, 2024 6:14 PM	9e1415e8
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ABCAM

Abcam

Last Close

1,103.00

13/12 17:52

Volume Today

3.18M

Avg: -